Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation

被引:269
作者
Berger, C
Flowers, ME
Warren, EH
Riddell, SR
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[2] Univ Washington, Dept Med, Seattle, WA 98195 USA
关键词
D O I
10.1182/blood-2005-08-3503
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The introduction of an inducible suicide gene such as the herpes simplex virus thymidine kinase (HSV-TK) might allow exploitation of the antitumor activity of donor T cells after allogeneic hematopoietic cell transplantation (HCT) without graft versus host disease. However, HSV-TK is foreign, and immune responses to gene-modified T cells could lead to their premature elimination. We show that after the infusion of HSV-TK-modified donor T cells to HCT recipients, CID8(+) and CD4(+) T-cell responses to HSV-TK are rapidly induced and coincide with the disappearance of transferred cells. Cytokine flow cytometry using an overlapping panel of HSV-TK peptides allowed rapid detection and cluantitation of HSV-TK-specific T cells in the blood and identified multiple immunogenic epitopes. Repeated infusion of modified T cells boosted the induced HSV-TK-specific T cells, which persisted as memory cells. These studies demonstrate the need for nonimmunogenic suicide genes and identify a strategy for detection of CD4(+) and CD8(+) T-cell responses to transgene products that should be generally applicable to monitoring patients on gene therapy trials. The potency of gene-modified T cells to elicit robust and durable immune responses imply this approach might be used for vaccination to elicit T-cell responses to viral or tumor antigens.
引用
收藏
页码:2294 / 2302
页数:9
相关论文
共 56 条
  • [51] Spencer DM, 2000, CURR OPIN MOL THER, V2, P433
  • [52] An inducible caspase 9 safety switch for T-cell therapy
    Straathof, KC
    Pulè, MA
    Yotnda, P
    Dotti, G
    Vanin, EF
    Brenner, MK
    Heslop, HE
    Spencer, DM
    Rooney, CM
    [J]. BLOOD, 2005, 105 (11) : 4247 - 4254
  • [53] A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease
    Thomis, DC
    Marktel, S
    Bonini, C
    Traversari, C
    Gilman, M
    Bordignon, C
    Clackson, T
    [J]. BLOOD, 2001, 97 (05) : 1249 - 1257
  • [54] Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft
    Tiberghien, P
    Ferrand, C
    Lioure, B
    Milpied, N
    Angonin, R
    Deconinck, E
    Certoux, JM
    Robinet, E
    Saas, P
    Petracca, B
    Juttner, C
    Reynolds, CW
    Longo, DL
    Herve, P
    Cahn, JY
    [J]. BLOOD, 2001, 97 (01) : 63 - 72
  • [55] Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors
    Verzeletti, S
    Bonini, C
    Marktel, S
    Nobili, N
    Ciceri, F
    Traversari, C
    Bordignon, C
    [J]. HUMAN GENE THERAPY, 1998, 9 (15) : 2243 - 2251
  • [56] Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo
    Yee, C
    Thompson, JA
    Roche, P
    Byrd, DR
    Lee, PP
    Piepkorn, M
    Kenyon, K
    Davis, MM
    Riddell, SR
    Greenberg, PD
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (11) : 1637 - 1643